Objectives: A recent study of community pharmacists in Canada reported that they required additional education. We conducted a survey of community pharmacists to evaluate the adequacy of education and training in oral anticancer agents in Japan. Methods: Between May and June 2014, community pharmacists were asked to complete a questionnaire by using two different survey strategies, one online and one via postal mail. Results: Three hundred community pharmacists responded to an online survey and 283 community pharmacists responded to a mailed survey. Only 6-10% of respondents felt that they had received adequate education in oncology or oral chemotherapy. Although 81% of Japanese pharmacists had attended at least one continuing education event related to oncology in the past 2 years, only 54% felt comfortable dispensing oral anticancer agents and only 40% felt comfortable educating patients about oral chemotherapy. In a multivariate analysis, confidence in educating patients about oral chemotherapy was associated with an understanding of chemotherapy cycles and doses (odds ratio = 4.89, 95% confidence interval [2.53-9.45]) and the number of continuing education events they had attended (odds ratio = 1.67, 95% confidence interval [1.35-2.08]). Conclusions: This is the first report to evaluate whether community pharmacists are equipped to ensure the safe use of oral anticancer agents in Japan. The results are similar to those previously reported for Canadian pharmacists, namely a low rate of positive responses for education in oncology and oral chemotherapy, demonstrating a similar need for additional education and training in oral chemotherapy.
Introduction
The development and use of oral chemotherapy has increased significantly in recent years. A 2008 report by the National Comprehensive Cancer Network (NCCN) predicted that usage rates would accelerate still further in the future (1) . Oral anticancer agents offer substantial benefits over parenteral anticancer therapies due to their convenient administration (2) , and existing data indicate that cancer patients prefer oral rather than injection treatments (3) (4) (5) (6) . To ensure safety, however, oral chemotherapy requires increased regulation of the way these drugs are ordered, dispensed, administered and monitored (7) . Several new oral chemotherapies have become available in Japan (2) , but outpatient management nevertheless remains challenging due to the potential for adverse drug reactions in the home (1, 8) . Indeed, Martin et al. (9) reported that adherence to an oral chemotherapy regimen was the main predictor of the molecular response to imatinib therapy in patients with chronic myeloid leukemia. Hence, patient management may be a key variable in the success of oral chemotherapies.
A nationwide survey revealed that the rate at which hospital pharmacists validate and review the accuracy of doctor's prescriptions was much lower for outpatients prescribed oral chemotherapy than for inpatients receiving parenteral chemotherapy (10, 11) . Against this background of inadequate hospital pharmacist intervention, community-based healthcare systems and community pharmacists play the most prominent roles in managing oral chemotherapy and ensuring safe treatment. However, although the role of community pharmacists is believed to be important, their actual effectiveness and reliability has not been studied in detail in Japan. In a recent study of community pharmacists in Canada, Abbott et al. reported that improving the standard of care for oncology patients treated with oral therapy required that community pharmacists undergo more education and training in oral anticancer agents (12) . Based on an interview survey, Butt et al. suggested that community pharmacies face significant challenges in their provision of oral chemotherapy services, and that community pharmacists aiming to implementing oral chemotherapy services in community pharmacies require educational and training opportunities, as well as the development of infrastructure to ensure drug safety (13) . Following the establishment of standards by the British Oncology Pharmacy Association (14) , the Japanese Society of Pharmaceutical Oncology published guidelines for oral chemotherapy in 2016, and an oncology pharmacy certification system for community pharmacy was set up somewhat earlier, in 2014. However, the efficacy of the guidelines in educating community pharmacists has not been evaluated, and requires knowledge of how well community pharmacies perform in the management of oral chemotherapy.
Here, we conducted a survey of community pharmacists to determine their capacity to safely administer and manage chemotherapy, and to evaluate the adequacy of education and training in oral anticancer agents that are available to such pharmacists in Japan.
Patients and methods
Between May and June 2014, community pharmacists were asked to complete the same questionnaire used by Abbott et al. (12) . The questionnaire was translated into Japanese with the permission of the authors of the original English language version (12) by a hospital pharmacist with English translation certification by the Japan Translation Federation. We added some questions and made modifications to a number of others to make the questionnaire more ptappropriate for community pharmacists in Japan. The questionnaire consisted of three basic areas: (i) respondent demographic characteristics and practice settings (Q1-Q5); (ii) pharmacist education (Q6-Q9) and (iii) pharmacy services for oral chemotherapy, and relationships with hospitals that prescribe oral chemotherapy (Q10-Q25). The study was approved by the Institutional Review Board of Meiji Pharmaceutical University (Approval #2526) and was conducted in accordance with all applicable ethical standards.
We used two different survey strategies, one online and one via postal mail. These two approaches were adopted in order to collect as much data as possible, and also so that we could compare the two survey types to assess their relative strengths and limitations. We did not divide subjects into postal and online groups.
Online survey
The online questionnaire surveyed 300 community pharmacists with experience in administering oral chemotherapy. The questionnaire was carried out using the services of the NEXTIT Research Institute (http://www.nextit.co.jp) which currently registers~4000 community pharmacists in Japan. NEXTIT sent an e-mail that explained the purpose of the questionnaire study to all 4000 pharmacists, requesting volunteers for the questionnaire among those with experience in dispensing oral chemotherapies and conducting medical consultation with oral chemotherapy patients. NEXTIT enrolled 500 pharmacists to cooperate with the study, and hosted the questionnaire survey on their website. The answers from the first 300 respondents were used in this report.
Mailed survey
We mailed our survey to 973 community pharmacies randomly selected from pharmacies established near Japanese governmentdesignated cancer care hospitals, which include District Designated Cancer Care Hospitals, Prefectural Designated Cancer Care Hospitals and National Cancer Center Hospitals using multistage sampling. These hospitals are the main providers of cancer therapy in Japan. Community pharmacies located close to these designated cancer care hospitals receive prescriptions mainly from the designated cancer care hospital they are located near to. We received 283 replies via postal mail or FAX. We did not experience technical trouble in receiving responses, but we could not be certain that some respondents did not FAX using an incorrect telephone number. This would have had the effect of reducing the net number of respondents, although we received no notification from recipients of such erroneous FAX transmissions from respondents, so have no evidence that they occurred.
Statistics
To detect factors associated with pharmacist confidence in the management of oral chemotherapy, we conducted multivariate logistic regression analysis of answers to Q13: 'I am comfortable educating patients about oral chemotherapy.' This statement is designed to assess how well the pharmacist understands oral chemotherapy and adverse drug reactions. For this analysis, we pooled data from the online and mailed surveys. Additionally, bivariate analyses were employed to examine differences in the background characteristics of community pharmacists, with the t-test used for continuous variables and the chi-square test for categorical variables. All data were analyzed using SPSS version 22.0 (SPSS Inc., Chicago, IL). A P value of <0.05 was considered statistically significant.
Results
Respondent demographic characteristics and practice settings: Q1-Q5
In total, 300 community pharmacists responded to the online survey, and 283 community pharmacists responded to the mailed survey (29%). Pharmacists from 43 of the 47 Japanese prefectures answered the online survey (91%), whereas pharmacists from 46 (97%) prefectures answered the mailed survey (Supplementary Table 1 ). Response rate for pharmacists at community pharmacies located close to designated cancer care hospitals was statistically higher for the mailed survey than for the online survey (72.1% vs 5.7%, P < 0.001). In both surveys, chain pharmacies accounted for 76% of respondents, while 19% were independent pharmacies. Between 75% and 85% of respondents dispensed >40 prescriptions per day, and were aged between 30 and 60 years old. The mailed survey group was significantly younger than the online survey group; however, respondents of both surveys had an average of~15 years of experience. The percentage of certified pharmacists was higher for the mailed survey than for the online survey (51.6% vs 40.7%, P < 0.01); however, both surveys yielded only a single respondent pharmacist with oncology pharmacy certification. In the online survey,~60% of respondents dispensed five or fewer prescriptions for oral anticancer agents each week, compared with >22% of mail survey respondents who dispensed >25 oral chemotherapy prescriptions per week. The mean number of oral chemotherapy prescriptions dispensed per week was significantly higher for mailed survey respondents than for online survey respondents (P < 0.001) ( Table 1 ).
Pharmacist education: Q6-Q9
Only 6.7% (39/583) of respondents felt that they had received adequate oncology education during their undergraduate degree. For oral chemotherapy specifically, the percentage was lower still, at 10.1% (59/583). Compared with these low rates, the percentage who felt they had received adequate oral chemotherapy education through a combination of their undergraduate degree and continuing education events or via their community practice was 64.0% (373/583). The percentage of respondents who had attended at least one continuing education event related to oncology in the past 2 years was 75%, consisting of 36.9% for 1-2 events (n = 215), 25.7% for 3-5 events (n = 150) and 18.5% for >6 events (n = 108). The incidence of positive answers was statistically higher in the mailed survey than in the online survey for Q8: 'Received adequate knowledge of oral chemotherapy through undergraduate degree, continuing education events or community practice' (P < 0.05) and Q9: 'What number of continuing education events related to oncology you have you attended in the past two years?' (P < 0.001) ( Table 2) .
Pharmacy services for oral chemotherapy
Knowledge, skills and confidence Respondents who felt they understood chemotherapy cycles and doses of oral chemotherapy comprised 79.9%, broken down as 'strongly agree' at 15.8% (92/583) and 'agree' at 64.2% (374/583). Respondents who claimed to feel comfortable managing the side effects of oral chemotherapy comprised 54.0%, broken down as 'strongly agree' at 9.4% (55/583) and 'agree' at 44.6% (260/583). Respondents who claimed to feel comfortable dispensing oral chemotherapy comprised 54.9%, with 'strongly agree' at 8.2% (48/ 583) and 'agree' at 46.7% (272/583). Respondents who claimed to feel comfortable educating patients about oral chemotherapy comprised 40.7%, with 'strongly agree' at 3.8% (22/583) and 'agree' at 36.9% (215/583).
Pharmacy services
Most respondents indicated that important education topics or sources of information for oral chemotherapy (Q19) were 'Medication consultation' (70%) and 'Adverse drug reactions' (73%); while for patient education tools, most used 'Pharmaceutical company-provided tools' (80%) and the 'Same information sheets as normal medicine' (56%) (Q24). Respondents who had received questions from oral chemotherapy patients comprised 77.2% (450/583); however, half of responders answered that the frequency was 'never' (n = 102, 17.5%) or '0-20%' of cases (n = 277, 47.5%). Frequently asked questions appear primarily related to 'adverse drug reactions' (77%), 'interactions' (67%), 'cost of medication' (58%), 'dose' (57%), 'length of therapy' (55%) and 'compliance' (55%). Respondents reporting difficulties in managing adverse drug reactions in oral chemotherapy patients comprised only 19.4%, with 'often' at 2.2% (13/583) and 'yes' at 17.2% (100/583).
Of the two pharmacological categories of oral chemotherapy, cytotoxics or hormonal drugs and molecular-targeted agents, we anticipated that community pharmacists would likely experience greater difficulty in managing molecular-targeted drugs, and the results of Q18 (Table 3 ) confirm this. More than half of community pharmacies did not stock 'regorafenib' (73.6%), 'temozolomide' (66.6%), 'sunitinib' (64.7%) or 'sorafenib' (54.2%). When questioned if difficulties had been experienced managing specific oral chemotherapy drugs, respondents answered positively for 'regorafenib' (52.6%), 'sunitinib' (51.0%), 'sorafenib' (47.2%), 'erlotinib' (45.0%), 'temozolmide' (44.6%), 'gefitinib' (36.1%), 'imatinib' (32.1%), 'capecitabine' (28.2%), 'S-1 (tegafur/oteracil/gimeracil)' (19.7%), 'exemestane' (16.2%) and 'tamoxifen' (15.1%). The percentages of pharmacists that felt comfortable using the average of all cytotoxics or hormonal drugs was statistically higher than those who felt comfortable using the average of all molecular-targeted agents (75.2 ± 12.2% vs 56.0 ± 8.2%, P = 0.013). Most community pharmacists were unfamiliar with the temozolomide, and 44% of respondents answered that they were uncomfortable administering it. Nevertheless, the drug is categorized as a cytotoxic, although it is used for brain tumors, which are not a major cancer type.
Patient education topics ranked in order of importance by the community pharmacists were 'adverse drug reactions' at 73.1% (426/583), 'medication consultation' at 70.7% (412/583), 'missed dose' at 49.2% (287/583), 'compliance' at 46.5% (271/583), 'drug interaction' at 30.2% (176/583), 'emesis' at 19.4% (113/583) and 'handling of medication' at 14.2% (83/583). Respondents who had in place a procedure to monitor compliance with oral chemotherapy comprised 70.3%, with 'strongly yes' at 6.2% (36/583) and 'yes' at 64.2% (374/583). Respondents indicated that the following criteria are relevant to safe oral chemotherapy: 'period of cycle' 81.8% (477/583), 'diagnosis' 66.0% (385/583), 'cancer notification' 65.2% (380/583), 'height/weight' 40.5% (236/583), 'body surface area' 35.0% (204/583) and 'privacy room/space' 32.6% (190/583). While 50.8% of respondents calculated oral chemotherapy doses according to body surface area, 43.6% of respondents did not calculate this way, because they were not provided with information about body surface area. A substantial percentage of community pharmacists (63.5%) felt they were not in an environment where they could obtain assistance for problems relating to oral chemotherapy from hospital pharmacists, and this ratio was higher among online survey respondents than mail survey respondents (73.7% vs 52.7%, P < 0.001) ( Table 4) .
Multivariate logistic regression analysis of pharmacist confidence in educating patients about oral chemotherapy
In a multivariate analysis, pharmacists' confidence in their ability to educate patients about oral chemotherapy was associated with an understanding of chemotherapy cycles and doses (odds ratio = 4.89, 95% confidence interval (CI) [2.53-9 .45]). It was also associated with the number of continuing education events that the pharmacist had attended (odds ratio = 1.67, 95% CI [1.35-2.08]). Pharmacist age, number of years of experience and number of oral chemotherapy prescriptions dispensed per week were not associated with confidence in educating patients about oral chemotherapy (Table 5) .
Discussion
This study represents the first analysis of the current status of pharmacy services for oral chemotherapy in community pharmacy settings. Our data reveal that more than half of community pharmacists experience difficulties in providing support to oral chemotherapy patients. Our analysis reveals that pharmacist confidence in educating patients about oral chemotherapy requires knowledge of this type of therapy and its administration, matching results from Canadian community pharmacists (12) . Our results thus n.s., no significant. Q1-1: According to definition of the American Pharmacists Association, a community pharmacy is defined as a 'chain community pharmacy' if the organization consists of four or more stores. If the organization consists of three or fewer stores, it is defined as an 'independent pharmacy'. Q2: Respondents' area demographics is in Supplementary Table 1. identify a clear need for additional education and training in oral chemotherapy. The cut-off value for positive answer, strongly agree and agree of 'Q13 I am comfortable educating patients about oral chemotherapy' was '1-2 continuing education events related to oncology in the past two years' calculated by receiver operating characteristic (ROC) analysis (area under the ROC = 0.62; sensitivity, 66%; and specificity, 59%). Likewise, our previous study that board certification was shown to be beneficial in terms of adherence to adequate chemotherapy in a hospital (11). Charpentier et al. (15) reported that community pharmacists who participated in educational programs have significantly improved confidence levels, and our survey showed continuing educational programs were one of the most important factors that enhanced confidence. Although our data did not assess a potential positive correlation between education programs and better clinical pharmacy services, confidence level is nevertheless vital in any clinical practice. Two key points in maintaining patient adherence to oral chemotherapy regimens are patient education about oral chemotherapy and suitable management of adverse drug reactions. Eliasson et al. reported that management of side effects and the use of reminders for taking doses of oral chemotherapy substantially improve patient adherence (16) . In the present study, we did not explore possible relationships between skills and confidence or knowledge for oral chemotherapy among community pharmacists. Our survey asked whether respondents were concerned with the level of community pharmacist education regarding oral chemotherapy. Although few negative answers were received for questions about the adequacy of education and monitoring of oral chemotherapy, many pharmacists choose 'neutral' answers to these questions, and our results also appear to show that unfamiliar agents in general, rather than specific drug classes, might be problematic for pharmacists.
The survey asked what information in prescriptions was important for conducting safe chemotherapy. Most respondents indicated that diagnosis of cancer type and administration cycle of oral chemotherapy were important factors. Most pharmacists answered that they calculate the dosage of oral chemotherapy drugs, but 40% of pharmacists appear not to do this because of a lack of information in the oral chemotherapy prescription regarding patient body surface area information. Indeed, although it is important and useful for pharmacists, it is generally uncommon for hospitals in Japan to provide such basic information, as well as other laboratory data about oral chemotherapy patients, due to privacy concerns. One notable exception is the National Cancer Center Hospital East, which provides data sheets to both patients and community pharmacists containing information about diagnosis, regimen and schedule of oral chemotherapy, and body surface area. There are some reports of hospitals providing laboratory information on prescriptions, which was an effective means of improving pharmacist decisions (17, 18) ; however, these reports were only recently published, and conveying patient information this way is still a new concept in Japan. In addition, safe treatment also requires communication systems between hospitals and community pharmacies. Among community pharmacists, only 35% felt they could readily consult hospital pharmacists for advice, whereas 63.5% felt they could not. Hence, there are clearly obstacles to communication between the two healthcare providers. Sakurai et al. reported the benefits of protocols designed to promote medication inquiries from community pharmacists to hospitals (19) . Such a system of communication may become more widely implemented in the future as a minimum requirement to ensure safe oral chemotherapy.
Almost 80% of respondents believed that they have the confidence to dispense oral chemotherapies. However, when we asked about their confidence to perform clinical interventions, positive responses were much lower (Q11-Q13). Only 6-12% of respondents felt that they had received adequate education. An understanding of oral chemotherapy is not straightforward to obtain, and education is difficult during an undergraduate degree, and most oral anticancer medicines are newly developed molecular targeting agents. Q18 revealed that, compared with cytotoxics or hormones, pharmacists are not familiar with handling molecular medicine. Moreover, more than half of respondents answered that they did not stock molecular anticancer drugs in their community pharmacy in Table 4 (Q18). The low rates at which molecular targeting drugs are stocked in community pharmacies could be due to their high prices. Only 5.7% of respondents answered that they worked near designated cancer care hospitals, and the number of oral Continued chemotherapy prescriptions dispensed per week was lower in the mailed survey than in our online survey. It is not unreasonable to stock expensive drugs in a community pharmacy; therefore, enhanced knowledge of such drugs is clearly an area that should improve pharmacist confidence in managing oral chemotherapies. We performed two different kinds of survey, one online and one mailed. Overall, the answers to these two surveys were similar, which enabled us to pool them and reduce possible biases among respondents to each of the two survey types. We consider that bias might exist among respondents to the online survey in particular; mailed respondents were relatively young, and worked for community pharmacies that are close to designated cancer care hospitals. Hence, such pharmacists dispense and handle oral chemotherapy drugs more routinely than the mailed survey respondents. This in turn may affect their attitude to oncology, including oral chemotherapy drugs, and their feeling that they received adequate understanding of oral chemotherapy Q18 is summarized in Table 4 . Detailed results of Q18 in online survey and mailed survey are in Supplementary Table 2. during their undergraduate degrees, in continuing education events, and via community practice. They had attended more continuing education events related to oncology in the past 2 years compared with mail survey respondents. In contrast, although the response rate was only 29%, we consider that the mailed survey may have evaluated the population in a more unbiased fashion. There was no obligation for community pharmacists to answer, and those who volunteered were probably motivated by a desire to improve the situation. When we planned the survey, we expected two categories of respondents: (i) community pharmacists who dispensed and managed oral chemotherapy in daily practice because they worked for pharmacies located near designated cancer care hospitals and received most prescriptions from these hospitals; and (ii) community pharmacists who rarely dispensed and managed oral chemotherapy because their pharmacies did not receive prescriptions for oral chemotherapy. Ultimately, the mailed survey predominantly attracted respondents of the first category, while the online survey attracted respondents of the second category. Even though the response rate of the mailed survey was only 29%, this was far higher than the 3% of the earlier Canadian study (12) . While the demographics of respondents were different in the mailed and online surveys, the 5.7% of online survey subjects who worked for community pharmacies located close to designated cancer care hospitals received oral chemotherapy prescriptions at a similar rate to the majority of mailed survey subjects located close to designated cancer care hospitals. Comparing these two groups, most answers to questions about education or attitudes to oral chemotherapy and patients were similar. This indicates that subjects with different backgrounds nevertheless provided similar answers regarding oral chemotherapy, and hence share similar views about outpatient oral chemotherapy prescriptions.
Our study has some limitations. In total, there are 57 784 community pharmacies in Japan (Ministry of Health, Labour and Welfare, Statistics Information <http://www.mhlw.go.jp/toukei/saikin/hw/eisei_ houkoku/14/dl/kekka5.pdf>, accessed on 24 July 2016). Our study used only 583 pharmacies. Furthermore, in the online survey, we selected pharmacists who had experience in oral chemotherapy, and for the mailed survey, we randomly selected 973 community pharmacies that were situated near or even next to designated cancer care hospitals. Another limitation is that our questionnaire survey could not evaluate the skills or competence of community pharmacists in oral chemotherapy. In addition, it is significant that 60% of respondents indicated that 'cancer notification'-meaning the doctor was not prevented by a family member from notifying the patient of the diagnosis of their own cancer-was important for the safe conduct of chemotherapy. This response reveals that there are still cancer patients in Japan who receive oral chemotherapy without knowledge of their own cancer.
In summary, our findings for Japanese pharmacists, which are similar to those previously reported for Canadian pharmacists (12) , demonstrate the need for additional education and training in oral chemotherapy. Our survey also revealed that only two pharmacists (0.3%) had certification related with oncology pharmacy. Oncology pharmacy board certifications, by either the Japanese Society of Hospital Pharmacists or the Japanese Society of Pharmaceutical Health Care and Sciences, focus on hospital pharmacists only. Therefore, the recent creation of a new board certification, the Accredited Pharmacists of Ambulatory Cancer Chemotherapy, by the Japanese Society of Pharmaceutical Oncology, which specifically focuses on community pharmacists, might be an important step in ensuring safe and reliable outpatient oral chemotherapy in Japan.
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